November is Pancreatic Cancer Awareness month and Stomach Cancer Awareness Month, and Friday the 10th is World NET (Neuroendocrine Tumours) Cancer Day.
The GI Cancer Institute is committed to changing the statistics for these cancers, and all gastro-intestinal GI cancers. Research is our best chance to improve outcomes but we need community support to get new research off the ground. Read about our current research for these cancers below.
Pancreatic cancer has one of the lowest survival rates of all cancers. Only 9.8% of people live for five years past their initial diagnosis. Around 10 people are diagnosed with pancreatic cancer every day, and there are 8 deaths.
The GI Cancer Institute is developing and conducting three clinical trials for pancreatic cancer. MASTERPLAN, which began recruiting patients on October 1, is treating pancreatic cancer with a highly targeted dose of radiotherapy as well as an innovative chemotherapy combination. RANDOMS is a proposed substudy of MASTERPLAN, which will gather valuable data on nutrition and body composition.
Researchers are currently seeking funding for the Neo-IMPACT trial, which will treat patients with immunotherapy at the start of treatment. If this treatment is effective, it could provide a new option for people with pancreatic cancer.
In 2019, an estimated 2,000 people will be diagnosed with stomach cancer, making it a relatively rare cancer. Worldwide, stomach cancer is the sixth most common cancer type and the third leading cause of cancer deaths.
The INTEGRATE II trial is investigating the use of the chemotherapy treatment regorafenib for gastro-oesophageal cancer, which occurs at the junction of the oesophagus and the stomach. Recruitment is currently open for participants in Australia and around the world.
NETs (Neuroendocrine tumours)
Neuroendocrine tumours (NETs) are slow-growing cancers that can develop throughout the digestive system. They form in the neuroendocrine system, a network of glands and nerve cells that produce and release hormones into the bloodstream to control body function. Approximately 4,276 people will be diagnosed with NETs in 2019.
The GI Cancer Institute is currently conducting two trials into NETs treatment. NABNEC is comparing two different types of chemotherapy for patients with advanced NETs to see whether there is the potential to improve survival outcomes. It is currently recruiting participants.
CONTROL NETs is investigating whether chemotherapy, radiopeptide therapy or a combination of both is the most promising treatment for improving the control of advanced NETs. It has finished recruiting participants and is now in follow-up.